AbbVie faces US amended antitrust claims over Humira
( November 4, 2026, 23:31 GMT | Official Statement) -- MLex Summary: Employee health funds filed an amended US antitrust complaint accusing AbbVie of conspiring to block biosimilar competition to its brand name drug Humira. According to the complaint, AbbVie entered into agreements with pharmacy benefit managers whereby, in exchange for payments, the PBMs ensured Humira would be positioned favorably on formularies, thereby thwarting the biosimilar competitors’ ability to win sales.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.